20/20 Biolabs, Inc. (AIDX) stock: key figures, P/E, revenue and dividend

Industrials · United States · ISIN US90138K1016

Price
0.20 USD
Market cap
2.61 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

20/20 Biolabs, Inc. financials

Fiscal year2025
Revenue2.05 m USD
Gross profit604,541.00 USD
Operating income-3.33 m USD
EBIT-3.60 m USD
Net income-3.74 m USD
Diluted EPS – continuing operations-0.76 USD

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.